MedTrace Logo

Role of Circulating MicroRNAs in Differentiating Psychological Disorders Among Women With Chronic Toxoplasmosis

NCT07346833 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2026-01-16

No results posted yet for this study

Summary

Chronic Toxoplasma gondii (T. gondii) infection is a widespread condition that can negatively affect brain function and is considered a risk factor for various psychiatric conditions, including depression and schizophrenia. This prospective observational study aims to investigate the expression levels of specific circulating microRNAs (miRNAs) in women diagnosed with schizophrenia, major depressive disorder, or bipolar disorder who also have chronic toxoplasmosis. By comparing these levels to patients without the infection, the study seeks to determine if these miRNAs can serve as biological markers to help differentiate between specific psychological disorders and identify the impact of chronic toxoplasmosis on mental health.

Conditions

  • Toxoplasmosis

Interventions

DIAGNOSTIC_TEST

Circulating miRNA Expression and T. gondii Serology

Serology: ELISA testing to detect anti-Toxoplasma IgG (confirming chronic infection) and IgM (excluding acute infection). Genetic Analysis: Quantitative Reverse-transcriptase PCR (qRT-PCR) to measure the expression levels of a predetermined panel of plasma miRNAs. Psychiatric Evaluation: Clinical diagnosis according to DSM-5 criteria.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Basma Salem, MD · Assistant Professor Clinical and Chemical Pathology. Faculty of Medicine, Benha University, Egypt

  • Dina Abd El hadi, MD · Assistant Professor Medical Parasitology. Faculty of Medicine, Benha University, Egypt

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-20
Primary Completion
2026-02-28
Completion
2026-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07346833 on ClinicalTrials.gov